STOCK TITAN

Idexx Laboratories Inc - IDXX STOCK NEWS

Welcome to our dedicated page for Idexx Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on Idexx Laboratories stock.

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a broad range of diagnostic and information technology-based products and services to practicing veterinarians across the globe. Headquartered in Southern Maine, the company operates through more than 70 locations worldwide, serving customers in over 175 countries and employing more than 11,000 people.

IDEXX’s primary business focuses on pet health, offering products such as in-clinic diagnostic tests, instrumentation, reference laboratory and telemedicine consultation services, and practice management software. These products enhance veterinarians' ability to provide advanced medical care, improve staff efficiency, and build more economically successful practices. The company is also involved in developing diagnostic tests for the global production animal industry, including poultry and livestock, and tests for the quality and safety of water.

An important recent achievement for IDEXX is the launch of the SNAP® Leish 4Dx® Test, designed to diagnose vector-borne diseases like canine leishmaniosis in regions where these diseases are endemic. This new test will be available in Europe and Asia starting February 2024. Another significant accomplishment is the expansion of the Fecal Dx® antigen testing platform, which includes the addition of Cystoisospora, a common intestinal parasite. This expansion will roll out in North America in March 2024 and globally by the third quarter of 2024.

IDEXX also launched Vello, a software solution aimed at improving communication between veterinary practices and pet owners. This tool supports better health outcomes by engaging pet owners through digital means and is integrated with IDEXX's existing practice management software like ezyVet®, Neo®, and Cornerstone®.

Financially, IDEXX is robust, with a diverse revenue stream sourced from various products and services, including diagnostic equipment, tests, and software solutions. Approximately 35% of its revenue comes from international markets. The company is a member of the S&P 500® Index, highlighting its significant role in the industry.

For more information about IDEXX’s products and services, visit idexx.com.

Rhea-AI Summary

IDEXX Laboratories reported Q3 2024 results with revenue of $976 million, showing 7% reported growth and 6% organic growth. The Companion Animal Group (CAG) segment grew 7% reported and 6% organic, while Water revenue increased 13%. Earnings per share reached $2.80, up 11% reported and 12% comparable, with operating margin expansion of 110 basis points. The company adjusted its 2024 revenue guidance to $3,865-$3,890 million, reducing previous estimates by ~1% due to macro conditions affecting U.S. veterinary clinic visits. The updated EPS outlook is narrowed to $10.37-$10.53, maintaining consistent midpoint compared to prior guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.79%
Tags
-
Rhea-AI Summary

IDEXX Laboratories reported strong Q3 2024 results with 7% revenue growth reaching $976 million. The company achieved 6% organic growth, driven by Companion Animal Group (CAG) performance and Water revenue growth of 13%. Earnings per share reached $2.80, up 11% as reported.

The company adjusted its 2024 revenue guidance to $3,865-$3,890 million, a reduction of $38 million, reflecting near-term impacts on growth from macro conditions affecting U.S. veterinary clinic visits. The updated EPS outlook range is $10.37-$10.53, maintaining consistent projections supported by solid operating margin performance and benefits from lower projected interest expense.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.79%
Tags
-
Rhea-AI Summary

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced the upcoming release of its 2024 third quarter financial results. The results will be made public on Thursday, October 31, 2024, before the market opens. Following the release, the company will host an analyst conference call at 8:30 a.m. EDT on the same day.

Investors and interested parties can access a live webcast of the conference call, along with a transcript of prepared remarks and the Q3 2024 Earnings Snapshot, through the IDEXX website at www.idexx.com/investors. An archived version of the webcast will be available after 1:00 p.m. ET and remain accessible for one year. For those preferring to listen via telephone, the call can be accessed by dialing 1-800-289-0462 or 1-323-794-2442 and using the passcode 205740.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
Rhea-AI Summary

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's President and CEO, Jay Mazelsky, along with Executive VP and CFO, Brian McKeon, will engage in a fireside chat on Wednesday, September 4, 2024, from 11:30 am to 12:05 pm (EDT).

Investors and interested parties can access a live audio webcast of the presentation through the IDEXX website at www.idexx.com/investors. For those unable to attend the live event, an archived version of the presentation will also be made available through the same link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
Rhea-AI Summary

IDEXX Laboratories (NASDAQ: IDXX) reported Q2 2024 results with revenue of $1,004 million, a 6% increase as reported and 7% organic growth. Companion Animal Group (CAG) revenue grew 6% as reported and 7% organic, while Water revenue increased 9% as reported and 10% organic. CAG Diagnostics recurring revenue grew 6% as reported and 7% organic. EPS was $2.44, down 9% as reported but up 15% on a comparable basis, excluding a $0.56 per share impact from a litigation expense accrual.

The company updated its 2024 guidance, projecting revenue of $3,885 - $3,945 million (6.2% - 7.8% growth) and EPS of $10.31 - $10.59. The EPS outlook was reduced by $0.56 at midpoint due to the litigation expense accrual. IDEXX maintains a strong position in pet healthcare innovation, with record Q2 premium instrument placements and 11% annual growth in its global premium instrument installed base.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
-
Rhea-AI Summary

IDEXX Laboratories (NASDAQ: IDXX) has announced a time change for its 2024 second quarter financial results conference call. The call will now take place at 9:00 am ET on Tuesday, August 6, 2024. This adjustment aims to minimize conflicts with other industry earnings announcements. Investors can access the live webcast, transcript, and Q2 2024 Earnings Snapshot through the company's website at www.idexx.com/investors. An archived version of the webcast will be available after 1:00 pm ET on the same day and will remain accessible for one year. For those preferring to listen via telephone, the call can be accessed by dialing 1-800-289-0459 or 1-773-305-6837 with passcode 399723.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences earnings
Rhea-AI Summary

IDEXX Laboratories, Inc. (NASDAQ: IDXX) has released its 2023 Corporate Responsibility Report, highlighting progress in pet healthcare innovation and corporate responsibility goals. Key achievements include:

Healthcare Advancements: Launch of IDEXX Cystatin B Test for kidney injury detection and development of new products like IDEXX inVue Dx™ Cellular Analyzer.

Community Support: Enabled access to care for over 245,000 animals in underserved communities in 2023.

Workplace Initiatives: Maintained gender balance in global management roles, supported women in STEM, and logged over 73,000 hours of employee learning and development.

Environmental Progress: Procured a virtual power purchase agreement for clean electricity in North America and installed a dual-source energy system at a European reference laboratory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary

IDEXX Laboratories (NASDAQ: IDXX) will release its 2024 second quarter financial results on August 6, 2024, before market opening. An analyst conference call will follow at 8:30 a.m. EDT, accessible via webcast and telephone. The webcast and a transcript will be available on IDEXX's investor website and archived for a year. In addition, IDEXX will hold its 2024 Investor Day on August 15, 2024, at its headquarters in Westbrook, Maine, from 8:00 a.m. to noon EDT. Institutional investors and analysts can attend in person with prior registration or follow the live webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary

IDEXX Laboratories has launched the Catalyst Pancreatic Lipase Test, designed for rapid detection of pancreatitis in cats and dogs.

The test provides quantitative results in under 10 minutes and will be available in the U.S. and Canada by September, followed by a global rollout in Q4 2024.

The test is part of IDEXX's Catalyst platform, which aims to enhance diagnostic capabilities for veterinarians worldwide. The Catalyst SmartQC Control, a new quality control system that is 90% faster than current methods, will also be launched in Q4 2024.

Both innovations aim to streamline diagnostic workflows and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary

IDEXX Laboratories (NASDAQ: IDXX) announced that Brian McKeon, EVP & CFO, and Michael Lane, EVP & GM of Reference Laboratories and IT, will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 29, 2024, from 10:55 am to 11:25 am (EDT). A live audio webcast will be available on IDEXX's website, with an archived edition accessible later.

The company also announced its 2024 Investor Day on August 15, 2024, at its headquarters in Westbrook, Maine, from 8:00 am to 12:00 pm (EDT). The event will be webcast live, with advance registration required for in-person attendance by institutional investors and analysts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences

FAQ

What is the current stock price of Idexx Laboratories (IDXX)?

The current stock price of Idexx Laboratories (IDXX) is $423.42 as of November 6, 2024.

What is the market cap of Idexx Laboratories (IDXX)?

The market cap of Idexx Laboratories (IDXX) is approximately 34.1B.

What is IDEXX Laboratories, Inc.?

IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a global leader in pet healthcare innovation, providing a wide range of diagnostic and information technology-based products and services to veterinarians worldwide.

Where is IDEXX Laboratories headquartered?

IDEXX Laboratories is headquartered in Southern Maine, USA.

What are some key products and services offered by IDEXX?

IDEXX offers in-clinic diagnostic tests, reference laboratory and telemedicine consultation services, practice management software, diagnostic tests for production animals, and tests for water safety.

What recent products has IDEXX Laboratories launched?

IDEXX has recently launched the SNAP® Leish 4Dx® Test for vector-borne diseases and expanded its Fecal Dx® antigen testing platform to include Cystoisospora.

How many countries does IDEXX Laboratories serve?

IDEXX Laboratories serves customers in over 175 countries.

How many people does IDEXX Laboratories employ?

IDEXX Laboratories employs more than 11,000 people globally.

What is the new software solution IDEXX launched?

IDEXX launched Vello, a software solution that connects veterinary practices with pet owners through modern digital tools, integrated with existing practice management software.

What percentage of IDEXX's revenue comes from international markets?

Approximately 35% of IDEXX’s revenue comes from international markets.

Is IDEXX part of any major stock index?

Yes, IDEXX Laboratories is a member of the S&P 500® Index.

Where can I find more information about IDEXX's products and services?

For more information, you can visit IDEXX's official website at idexx.com.

Idexx Laboratories Inc

Nasdaq:IDXX

IDXX Rankings

IDXX Stock Data

34.09B
81.89M
0.94%
96.12%
2.78%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
WESTBROOK